Cannabis Science Inc (OTCMKTS:CBIS) informed that it has entered into a one-year deal with Derwin A. Wallace to offer financial and investor relations services. He will focus on expanding and developing the Company’s financial communications with the retails and institutional investment communities and start coverage from research analysts following a broad financial and investor relations plan.
Me. Wallace said that he is committed to putting all of his operational and financial resources to work to assist expedite Cannabis Science processes, and he is looking forward to communicate with company’s shareholders about the several drug development programs, patient education systems strategies and product releases in motion.
He said that he expects that his initiatives should speed up Cannabis Science project results and enhance the operational cash flow. There are a number of key projects underway, such as the California and Spain product launch, Netherlands pre-lab discussions, Italy, Africa and London drug development projects, Washington and Colorado State formulation releases, and NY State and Michigan state initiatives. The estimated potential revenue reflects the ongoing projects. The smart strategic measure the company is making implies the future of medical cannabis is here.
The management view
Mr. Raymond C. Dabney, the President and CEO of Cannabis Science stated that the latest step reflects the company’s commitment towards its shareholders to enhance shareholder value by setting into motion the $5 million-$25 million and larger funds raises necessary to take the Company and its wide range of products to the next level. There is lot more things going on in the industry of medical cannabis and with such instant change, analysts and investors need to be prepared to make quick, informed decisions. Adding Wallace to the company’s team is one of the most significant steps.
In last trading session, Cannabis Science Inc (OTCMKTS:CBIS) stock price surged 2.56% to close at $0.0440 with share volume of 1.64 million.